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Over the last couple of years, there have been numerous studies investigating the efficacy of ketamine, 
a non-competitive N-methyl-d-aspartic acid (NMDA) receptor antagonist as a rapid antidepressant. 
Most of the existing published literature describes the purported effectiveness of ketamine as a rapid 
antidepressant. The clinical efficacy of intravenous ketamine in the reduction of suicidal ideations 
ranged between that of 29% to as much as 79%. Researchers have noted the transient nature of 
intravenous ketamine’s rapid antidepressant efficacy and hence has recommended for long-term 
continued administration (1, 2). Clearly, with long-term utilization of ketamine, there are safety 
concerns and adverse effects that need to be considered. Prior systematic reviews have highlighted 
the acute adverse effects that could potential arise from the administration of intravenous ketamine 
(3). These adverse effects include that of dissociation, perceptual abnormalities, confusion, and 
transient instability in vital signs (3). Although studies have shown that serial infusions of ketamine 
in the short term (of 4 weeks) does not result in cognitive impairments (4), other studies have dem-
onstrated that the administration of ketamine chronically would lead to memory impairments (5). 
More recently, Morgan et al. (5) in their recent article highlighted not only the increasing incidence 
of ketamine abuse globally but have also highlighted the mechanisms and implications of ketamine 
have on spatial memory. According to their study of 11 participants (of which 1 participants have 
had another mental health condition) who have been using ketamine recreationally, they discovered, 
through functional imaging studies that ketamine abusers experience spatial memory disturbances 
largely due to decreased activation in their right hippocampus and left parahippocampus gyrus 
(5). Morgan et al. (5) in their imaging studies also highlighted that chronic ketamine abusers do 
tend to experience dissociative symptoms, which are accounted for due to increased hippocampal 
activation. In addition, the functional studies also revealed that there are underlying disruption in 
the medial temporal lobe functioning. These resultant disruptions might also result in the psychotic 
symptoms that long-term ketamine abusers might experience. Clearly, the findings presented by 
Morgan et al. (5) are concerning if intravenous ketamine is being approved clinically and depressed 
individuals need to be receiving continuous administrations of intravenous ketamine. Although 
ketamine might seem like a promising antidepressant that could relieve treatment refractory depres-
sive symptoms, the induction of memory impairments in the longer term is of concern. Memory 
impairments would result in further disabilities and consequential reduction in the overall quality of 
life. Aside to ketamine’s potential to result in memory impairments if used chronically, the chronic 
usage of ketamine does result in urological problems, such as cystitis (6).
Although it is commonly assumed that acute and chronic usage of ketamine would have deleteri-
ous effect on cognition, researchers who have looked at the efficacy of sublingual ketamine, which 
despite its inherent lower bioavailability of 30%, have highlighted that sublingual variant of ketamine 
might helped to mitigate against the cognitive adverse effects (7). In a recent trial, 77% of patients 
demonstrated not only improvement in their mood but also their cognition (7). Lee et al. (8) in their 
recent systematic review proposed the procognitive efficacy of intravenous ketamine. Lee et al. (8) 
recent findings raises much discrepancies and controversies with the previous established findings 
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FiGURE 1 | Overview of ketamine and its precognitive effects.
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of ketamine on cognition. Based on Lee et  al. (8) systematic 
review, it has been shown in studies that acute administration 
of low dosages of ketamine not only did not affect memory but 
also helped in terms of improving visual memory, simple work-
ing memory, and complex working memory in individuals with 
treatment-resistant depression. It has been proposed that acutely, 
at low doses, ketamine does have procognitive efficacy through its 
mechanism of action on the intracellular proteins, such as BDNF 
and mTORC1. Through working on these intracellular proteins, 
executive functioning is also affected (Figure  1). Lee et  al. (8) 
proposed that ketamine’s acute effect on cognition might be the 
mediating factor that helps in the acute reduction of depressive 
symptoms and hence, the acute relief of suicidal ideations. It is 
postulated that suicidal ideations and planning for a suicide act 
involves much executive functioning capability. Usually, dysfunc-
tional executive control would lead to poor impulse control and 
hence disinhibition. Thus, ketamine, if it does have procognitive 
effects could help improve the cognitive dysfunctions that usually 
accompanies treatment-resistant depression, as well as reduce the 
degree of acute suicidal ideations, through the enhancements of 
better executive functioning and control.
Much of the current studies have focused on investigat-
ing the efficacy of ketamine as a rapid antidepressant. Given 
the concerns about the adverse effects that might arise from 
the repeated administration, there has been a drive toward 
evaluating the potential of racemic mixture of ketamine. More 
recent studies have started to determine if the clinical efficacy 
of intravenous ketamine is comparable to that of conventional 
antidepressant, and whether ketamine could be used as an 
added augmentation strategy. Given the recent controversy 
about the commonly believed adverse effects of ketamine on 
cognition, this is certainly an area that deserves more research 
work to look into. In order to better understand whether keta-
mine has truly a procognitive effect, it would be worthwhile to 
compare sublingual or racemic variant of ketamine against 
antidepressants, such as Vortioxetine (9, 10), which have been 
hypothesized to have procognitive effects through its modula-
tion of the 5HT7 and the 5HT3 receptors. Comparison of the 
racemic variant [R(−) variant of ketamine] would be key, given 
that prior studies have highlighted how the R(−) variant have 
had inherent greater potency and longer acting antidepressant 
efficacy (11).
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